Illumina, Inc.

809 articles with Illumina, Inc.

• Illumina Reports Financial Results for Third Quarter of Fiscal Year 2020

  10/29/2020

  Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the third quarter of fiscal year 2020. Third quarter 2020 results reflect strong sequential growth: Revenue of $794 million, an increase of 26% compared to the second quarter of 2020 and a 12% decrease compared to $907 million in the prior year period GAAP net income attributable to Illumina stockholders for the quarter of $179 milli

• Illumina to Announce Third Quarter 2020 Financial Results on Thursday, October 29, 2020

  9/28/2020

  Illumina, Inc. announced that it will issue results for the third quarter 2020 following the close of market on Thursday, October 29, 2020.

• Illumina to Webcast Upcoming Investor Conference Presentation - Sep 23, 2020

  9/23/2020

  Illumina, Inc. announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.

• Illumina to Acquire GRAIL to Launch New Era of Cancer Detection

  9/21/2020

  Accelerates Commercialization and Adoption of Transformative Multi-Cancer Screening Test with Potential to Detect More Cancers Earlier and Enable Better Outcomes

• 

  BioSpace Movers & Shakers, Aug. 28

  8/28/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Illumina Welcomes Kathryne Reeves as Chief Marketing Officer

  8/25/2020

  Illumina (NASDAQ: ILMN) announced today that Kathryne Reeves will join the company as Chief Marketing Officer on September 28, 2020. Reeves brings more than 25 years of marketing and general management experience in roles across the healthcare, technology, and consumer products industries. Reeves will report to Chief Executive Officer, Francis deSouza. This press release features multimedia. View the full release here: htt

• Illumina to Webcast Upcoming Investor Conference Presentation - Aug 07, 2020

  8/7/2020

  Illumina, Inc. announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.

• Illumina Announces the NovaSeqTM 6000 v1.5 Reagent Kit Unlocking Deeper Discoveries with the $600 Genome

  8/6/2020

  Illumina, Inc. (Nasdaq:ILMN). The power to make bigger discoveries is here with the launch of NovaSeqTM 6000 v1.5 Reagent Kit.

• Illumina Reports Financial Results for Second Quarter of Fiscal Year 2020

  8/6/2020

  Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2020.

• Illumina to Announce Second Quarter 2020 Financial Results on Thursday, August 6, 2020

  7/16/2020

  Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2020 following the close of market on Thursday, August 6, 2020.

• Illumina Launches TruSight Software Suite to Accelerate the Identification of Genetic Diseases

  7/8/2020

  Illumina, Inc. (NASDAQ: ILMN) is bringing turn-key data analysis solutions to accelerate and facilitate the adoption of whole-genome sequencing with the launch of the TruSight™ Software Suite . TruSight Software delivers ready-made infrastructure to realize the full potential of whol

• PathGroup Selected as Early Access Partner for Launch of Illumina’s Sequencing-Based COVID-19 Diagnostic Test

  6/23/2020

  PathGroup, one of the largest private providers of pathology, clinical and molecular laboratory services in the United States, today announced that the company has been selected as an early access partner for the launch of Illumina’s new sequencing-based COVID-19 test, COVIDSeq™

• Illumina Accelerator Welcomes First Global Cohort of Genomics Startups

  6/23/2020

  Companies Advancing Genomics Applications in Therapeutics, Diagnostics and Research Tools

• Imagia Partners with Illumina to Scale Discoveries Across Genomic and Clinical Data

  6/22/2020

  Advanced AI-discovery platform Imagia EVIDENS™ to link analysis of genomic data to patient outcomes for reproducible data-driven precision medicine research

• Illumina Acquires BlueBee to Accelerate Processing, Analysis and Sharing of Next Generation Sequencing Data at Scale

  6/17/2020

  Illumina, Inc. (NASDAQ: ILMN) is enhancing its capabilities to analyze and interpret the data produced by its sequencing systems with the acquisition of BlueBee, a cloud-based software company that provides genomics analysis solutions for research and clinical customers

• 

  Biopharma Update on the Novel Coronavirus: June 12

  6/12/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.

• Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test

  6/10/2020

  Illumina, Inc. is paving the way for large-scale, next-generation sequencing-based COVID-19 testing.

• Coronavirus (COVID-19) Update: FDA Authorizes First Next Generation Sequence Test for Diagnosing COVID-19

  6/10/2020

  The U.S. Food and Drug Administration issued an emergency use authorization to Illumina, Inc. for the first COVID-19 diagnostic test utilizing next generation sequence technology.

• 

  Biopharma Update on the Novel Coronavirus: June 10

  6/10/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.

• Ginkgo Bioworks to Build Infrastructure for Rapid Epidemic Response with $70MM Investment

  5/28/2020

  Strategic investment from Illumina and others enables large-scale COVID-19 testing using next generation sequencing